Johnson & Johnson’s Janssen Biotech, Inc., submitted an application to the U.S. FDA requesting Emergency Use Authorization for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on efficacy and safety data from the Phase 3 ENSEMBLE trial demonstrating the investigational single-dose vaccine met all primary a